Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells

Molecular and Cellular Endocrinology

Volumn 192, Issue 1-2, 2002, Pages 93-104

  Sakamoto, Takako ^a   Eguchi, Hidetaka ^b   Omoto, Yoko ^b   Ayabe, Takuya ^a   Mori, Hiroyuki ^a   Hayashi, Shin ichi ^b  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

Endometrial cancer; Estrogen receptor ; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTROGEN RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; 4-HYDROXYTAMOXIFEN; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL SPECIFICITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; ADENOCARCINOMA; BIOLOGICAL MODEL; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG SCREENING; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSACTIVATION;

ADENOCARCINOMA; BREAST NEOPLASMS; CARCINOMA; COMPARATIVE STUDY; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR STEM CELL ASSAY; ESTROGEN RECEPTOR ALPHA; HUMANS;

EID: 0037188809     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00086-2     Document Type: Article

References (55)

1. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
2. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line)
3. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
4. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells
5. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
6. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer
7. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
8. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
9. A transcriptional co-repressor that interacts with nuclear hormone receptors
10. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
11. Molecular mechanisms of selective estrogen receptor modulator (SERM) action
12. Tamoxifen for early breast cancer: An overview of the randomised trials
13. Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene
14. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α
15. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
16. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
17. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
18. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma
19. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
20. Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer
21. Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line)
22. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
23. Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element
24. Development and characterization of established cell lines from primary and metastatic regions of human endometrial adenocarcinoma
25. Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 β and progesterone receptors
26. Biological characteristics of adenocarcinoma cell line (HOUA-I) and B-lymphoblastoid cell line (HOUA-II) established from the same tissue of endometrial adenocarcinoma
27. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa)
28. Estrogen receptor α rapidly activates the IGF-1 receptor pathway
29. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
30. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways
31. P300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains
32. Establishment of a cell line of human endometrial adenocarcinoma in vitro
33. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer
34. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex
35. 3-PKC-α signal transduction pathway in HEPG2 cells
36. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation
37. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells
38. The nuclear receptor ligand-binding domain: Structure and function
39. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models
40. Establishment of eighteen clones of Ishikawa cells
41. Expression, function, and clinical implications of the estrogen receptor β in human lung cancers
42. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
43. Estrogens in the causation of breast, endometrial and ovarian cancers - Evidence and hypotheses from epidemiological findings
44. KLE: A cell line with defective estrogen receptor derived from undifferentiated endometrial cancer
45. Phosphorylation of steroid receptor coactivator-1: Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway
46. Changes in expression of estrogen receptors α and β in relation to progesterone receptor and pS2 status in normal and malignant endometrium
47. MDM2 enhances the function of estrogen receptor α in human breast cancer cells
48. Expression of a repressor of estrogen receptor activity in human breast tumors: Relationship to some known prognostic markers
49. Estrogen receptor cofactors expression in breast and endometrial human cancer cells
50. Prognostic value of steroid hormone receptors: Multivariate analysis of systemically untreated patients with node negative primary breast cancer
51. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
52. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
53. Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture
54. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
55. Estrogen receptor activation function 1 works by binding p160 coactivator proteins